Cancer Vaccine Development Solution

Creative Biolabs is a premier provider of cancer vaccine development solutions, offering end-to-end customized services from antigen discovery, vaccine design to preclinical validation and process optimization. Utilizing advanced platforms and profound expertise, we accelerate clients' progress across various oncology research fields, resolving complex target and immunosuppressive microenvironment challenges to help achieve breakthroughs in cancer immunotherapy.

Cancer Vaccine Design: Concepts and Key Considerations

The core of next-generation cancer vaccine design lies in breaking tumor immune tolerance and inducing a durable, potent T-cell immune response. Among these, personalized neoantigen vaccines are a current hot research topic, targeting patient-specific somatic mutations for precision therapy.

Key Design Considerations:

Neoantigen Prediction Accuracy

Using AI/machine learning algorithms to improve the accuracy of MHC binding affinity and immunogenicity prediction.

Tumor Microenvironment (TME) Modulation

Designing vaccines to overcome the immunosuppressive effects of the TME, for example, by co-delivering adjuvants or immune checkpoint inhibitors.

Delivery System Optimization

Selecting the optimal delivery vehicle (e.g., mRNA LNP, viral vectors, DC cells) for efficient antigen delivery to antigen-presenting cells.

Safety and Manufacturability

Ensuring the long-term stability of the vaccine formulation and the high-quality requirements for large-scale production.

Comprehensive Cancer Vaccine Development Services

Target Identification Challenges

Resolving the inefficiency and uncertainty of identifying tumor-specific antigens/neoantigens.

Insufficient Immunogenicity

Enhancing the immune activation potential of vaccine candidates in vivo through adjuvant and delivery system optimization.

Complex Project Pathways

Providing expert project management and high-standard production support to accelerate product translation towards next-stage applications.

Customization Needs

Offering highly personalized vaccine design and assessment programs for rare cancers or complex combination therapies.

Detailed Cancer Disease Vaccines

Cutaneous Cancer related Vaccine Development	Head and Neck Cancer related Vaccine Development
Genitourinary Cancer related Vaccine Development	Blood Cancer related Vaccine Development
Gynecologic Cancer related Vaccine Development	Brain Tumor related Vaccine Development
Gastrointestinal Cancer related Vaccine Development	Sarcomas related Vaccine Development
Breast Cancer related Vaccine Development	Pediatric Cancer related Vaccine Development
Lung Cancer related Vaccine Development	Neuroendocrine Tumor related Vaccine Development Services

Cutting-Edge Platforms and Innovative Technologies

AI-Driven Neoantigen Prediction

Utilizing deep learning models and advanced bioinformatics to precisely screen patient-specific, highly immunogenic neoantigen targets.

mRNA/DNA LNP Delivery System

Providing optimized Lipid Nanoparticle (LNP) formulations to ensure high-efficiency, stable delivery and in vivo expression of nucleic acid vaccines.

High-Standard Cell Vaccine Preparation

Includes the development and production of high-standard preparation processes for Dendritic Cell (DC) vaccines and tumor cell vaccines, ensuring product purity and activity.

Cancer Vaccine Preclinical Research Standard Workflow

Target Discovery and Vaccine Design

Conducting tumor genomic sequencing, neoantigen prediction, and screening. Selecting the optimal vaccine type and vector based on antigen characteristics (e.g., peptide, nucleic acid, cell).

Formulation Optimization and Early Process Verification

Optimizing vaccine adjuvant selection, delivery systems (e.g., LNP), and formulation stability. Establishing a pilot-scale process that meets industry high standards to ensure quality controllability.

In Vivo/In Vitro Efficacy and Safety Assessment

Assessing the vaccine's immunogenicity, efficacy, and safety (in vivo PK/PD, GLP toxicology) in in vivo and in vitro models. Generating key assessment data required for project advancement.

Data Feedback and Interpretation

Providing complete raw experimental data, high-quality project summary reports, and professional biological interpretation. Experts will communicate deeply with the client to assist in determining the next project strategy.

Partner with Creative Biolabs Now!

Creative Biolabs Core Advantages

One-Stop End-to-End Service

Full process support from early Proof-of-Concept to the later validation stage, significantly shortening your R&D cycle.

Cutting-Edge Technology Platforms

Integrating AI neoantigen screening, LNP formulation optimization, and various viral/non-viral vector platforms.

High-Standard Quality Management

Providing high-quality raw materials and vaccine finished product manufacturing that meets industry leading standards, ensuring the success rate of downstream applications.

Highly Customized and Flexible

Tailoring solutions to your specific cancer type and antigen requirements, ensuring high alignment with research and clinical goals.

A slide highlighting the Core Advantages of Creative Biolabs regarding the Cancer Vaccine Development Solution.

Case Study

HPV16 E7-HSP70C Fusion Protein Cervical Cancer Vaccine

Background

A study aimed to develop a therapeutic vaccine against HPV16-related cervical cancer, addressing HPV's role in ~70% of cases and limited efficacy of existing treatments. It targeted HPV16 E7 (oncoprotein) fused with HSP70C (heat-shock protein fragment) to enhance antigen presentation and anti-tumor immunity.

Solution

E7-HSP70C fusion protein was expressed/purified. C57BL/6 mice bearing TC-1 (HPV16⁺) tumors were grouped: E7-HSP70C, E7 alone, HSP70C alone, or PBS. Vaccinations (3×, 1-week interval) were given; immunity assessed via ELISA (antibodies) and flow cytometry (CD8⁺ T cells); tumor growth/survival monitored.

Result

E7-HSP70C induced higher anti-E7 IgG titres and CD8⁺ T-cell infiltration vs controls. It significantly inhibited tumor growth (tumor volume ~40% of PBS group) and prolonged survival (60% survival at 60 days vs 0% in controls). The fusion protein enhanced anti-tumor immunity, supporting its therapeutic potential.

A slide displaying the identification of candidate neoantigens in SKCM (Skin Cutaneous Melanoma).

Identification of candidate neoantigens in SKCM.
Yang, Ronghua, et al. "Bioinformatics analysis reveals novel tumor antigens and immune subtypes of skin cutaneous melanoma contributing to mRNA vaccine development." Frontiers in Immunology 16 (2025): 1520505. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2025.1520505

Customer Reviews

"The Creative Biolabs team provided unparalleled professional support in complex DC vaccine design. Their high-quality production process was transparent and efficient, helping us smoothly complete the high-stage project validation."

- Dr. Lin C.,

CEO, Biotechnology Company

"We particularly appreciate their AI tool for neoantigen prediction. The prediction accuracy was significantly higher than our internal testing, which greatly saved us time and R&D costs."

- Jason M.,

R&D Director, Multinational Pharmaceutical Company

"As a startup, we needed flexible and comprehensive support. Creative Biolabs not only solved our technical difficulties but also provided valuable strategic advice, making them a true strategic partner."

- Sarah K.,

Principal Investigator, Academic Lab

Cancer Vaccine Development Solutions: Frequently Asked Questions

What types of cancer vaccine development can Creative Biolabs support?

We offer comprehensive support for various cancer vaccine types, including: personalized neoantigen vaccines, DNA/mRNA nucleic acid vaccines, viral vector vaccines, dendritic cell (DC) vaccines, tumor cell vaccines, and recombinant protein/peptide vaccines.

What is the typical timeline for neoantigen screening?

Utilizing our advanced Neo-Predict™ AI platform, the process from obtaining WES data to the final list of highly immunogenic neoantigen targets can be completed in as fast as 1 week, achieving rapid delivery.

How do you select the most suitable vaccine delivery system?

Our expert team provides customized delivery system assessment and optimization advice based on your antigen characteristics (e.g., immunogenicity), target cell type, and intended route of administration. This primarily includes LNP, various viral vectors (AAV, Lentivirus, etc.), and adjuvant systems.

How does Creative Biolabs help us address the challenges of the Tumor Microenvironment (TME)?

We design strategic combination therapies by co-delivering immune-modulating molecules or utilizing vectors with TME-penetrating capabilities (such as certain viral vectors), aiming to reverse immune suppression and enhance T-cell infiltration and killing induced by the vaccine.

What preclinical efficacy assessment models do you provide for cancer vaccines?

We offer a range of validated in vivo and in vitro models, including syngeneic tumor models, humanized mouse models, and specialized immune response assays (e.g., flow cytometry), to comprehensively evaluate the vaccine's efficacy and mechanism of action.

Custom Solutions for Cancer Vaccine Development

Your unique oncology research deserves a truly tailored approach. If you need to customize your tumor vaccine research strategy, partner with us at Creative Biolabs, and let us provide the powerful, customized support needed to accelerate your journey to clinical success!

Schedule Your Consultation

Featured Resources

Reference image of vaccine-resources-1, containing materials relevant to vaccine research and development.

Download Resources

Visual of vaccine-literature-1, representing academic or technical literature focused on vaccine studies.